Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD

BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhan, Milo A., Yu, Tsung, Boyd, Cynthia M., ter Riet, Gerben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490602/
https://www.ncbi.nlm.nih.gov/pubmed/26137986
http://dx.doi.org/10.1186/s12916-015-0398-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490602/
https://www.ncbi.nlm.nih.gov/pubmed/26137986
http://dx.doi.org/10.1186/s12916-015-0398-0

Ejemplares similares